[go: up one dir, main page]

DK1993515T3 - Fremgangsmåde til solubilisering, dispergering og stabilisering af stoffer, produkter, der er fremstillet efter fremgangsmåden og anvendelsen af samme - Google Patents

Fremgangsmåde til solubilisering, dispergering og stabilisering af stoffer, produkter, der er fremstillet efter fremgangsmåden og anvendelsen af samme

Info

Publication number
DK1993515T3
DK1993515T3 DK07710794T DK07710794T DK1993515T3 DK 1993515 T3 DK1993515 T3 DK 1993515T3 DK 07710794 T DK07710794 T DK 07710794T DK 07710794 T DK07710794 T DK 07710794T DK 1993515 T3 DK1993515 T3 DK 1993515T3
Authority
DK
Denmark
Prior art keywords
same
poloxamer
solubilizing
dispersing
application
Prior art date
Application number
DK07710794T
Other languages
English (en)
Inventor
Hanspeter Strobel
Original Assignee
Laboswiss Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboswiss Ag filed Critical Laboswiss Ag
Application granted granted Critical
Publication of DK1993515T3 publication Critical patent/DK1993515T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A01N25/04Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/63Arthropods
    • A61K35/64Insects, e.g. bees, wasps or fleas
    • A61K35/644Beeswax; Propolis; Royal jelly; Honey
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0291Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/678Tocopherol, i.e. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/90Block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/987Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
    • A61K8/988Honey; Royal jelly, Propolis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/02Preparations for cleaning the hair

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Animal Husbandry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
DK07710794T 2006-03-10 2007-03-09 Fremgangsmåde til solubilisering, dispergering og stabilisering af stoffer, produkter, der er fremstillet efter fremgangsmåden og anvendelsen af samme DK1993515T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH3772006 2006-03-10
PCT/CH2007/000131 WO2007104173A2 (de) 2006-03-10 2007-03-09 Verfahren zum solubilisieren, dispergieren und stabilisieren von stoffen, nach dem verfahren hergestellte erzeugnisse sowie die verwendung derselben

Publications (1)

Publication Number Publication Date
DK1993515T3 true DK1993515T3 (da) 2009-12-07

Family

ID=38137765

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07710794T DK1993515T3 (da) 2006-03-10 2007-03-09 Fremgangsmåde til solubilisering, dispergering og stabilisering af stoffer, produkter, der er fremstillet efter fremgangsmåden og anvendelsen af samme

Country Status (17)

Country Link
US (2) US8703195B2 (da)
EP (1) EP1993515B1 (da)
JP (2) JP5678359B2 (da)
KR (1) KR101433962B1 (da)
CN (1) CN101400337A (da)
AT (1) ATE437627T1 (da)
AU (1) AU2007224940B2 (da)
BR (1) BRPI0708773B1 (da)
CA (1) CA2643389C (da)
DE (1) DE502007001190D1 (da)
DK (1) DK1993515T3 (da)
EA (1) EA026670B1 (da)
ES (1) ES2330898T3 (da)
HR (1) HRP20090573T1 (da)
PL (1) PL1993515T3 (da)
PT (1) PT1993515E (da)
WO (1) WO2007104173A2 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008306192A1 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of leptin (22-56 ) as a therapeutic agent
WO2009040068A2 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
KR20100057641A (ko) 2007-09-11 2010-05-31 몬도바이오테크 래보래토리즈 아게 인터메딘 47 및 53 펩티드의 치료적 용도
WO2009040019A2 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009033781A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
AU2008297524A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of Thymopentin as a therapeutic agent
RU2010114051A (ru) 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение grf-1(1-29) и кортиколиберина в качестве терапевтических средств
AU2008303919A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of angiotensin II as a therapeutic agent in the treatment of eg S. pneumoniae infection
JP5491396B2 (ja) 2007-09-11 2014-05-14 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのデフェンシンペプチドの使用
WO2009040006A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Spantide for therapeutic uses
KR20100061487A (ko) 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 펩티드 yglf 및 kvlpvpq와의 배합물의 치료적 용도
US20100184675A1 (en) 2007-09-11 2010-07-22 Dorian Bevec Use of glucagon (1-29) alone or in combination with neuropeptide w30 as a therapeutic agent
KR20100057050A (ko) 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 데슬로렐린 및 마스토파란의 용도
US20100204150A1 (en) 2007-09-11 2010-08-12 Dorian Bevec Use of a peptide as a therapeutic agent
US10519504B2 (en) 2009-05-11 2019-12-31 Berg Llc Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
EP2359702B1 (en) 2010-01-22 2014-06-04 Symrise AG Solubilization agent for solubilizing polyphenols, flavonoids and/or diterpenoid glucosides
US11400058B2 (en) * 2010-03-12 2022-08-02 Berg Llc Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof
EP2390284B2 (en) 2010-05-28 2017-03-15 Omya International AG Process for manufacturing high solids suspensions of mineral materials
EP2694463B8 (en) 2011-04-04 2019-10-09 Berg LLC Treating central nervous system tumors with coenzyme q10
EA201490047A1 (ru) 2011-06-17 2014-08-29 Берг Ллк Ингаляционные фармацевтические композиции
JP5869856B2 (ja) * 2011-11-30 2016-02-24 キユーピー株式会社 容器入り大根おろし含有液状調味料
BRPI1106762A2 (pt) * 2011-12-22 2013-11-05 Bioactive Biomateriais Ltda Composição polimérica contendo bioativos naturais aplicáveis em formulações farmacêuticas e cosméticas
KR101451401B1 (ko) * 2012-12-14 2014-10-22 주식회사 휴메딕스 비타민 c와 비타민 e의 컨쥬게이트 및 그를 포함하는 항산화제
JP6122646B2 (ja) * 2013-01-23 2017-04-26 昭和電工株式会社 皮膚外用剤
EA032775B1 (ru) 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
BR112015027112A2 (pt) * 2013-05-06 2017-07-25 Basf Se uso de uma mistura, e, formulação de ingrediente ativo aquoso
JP6232807B2 (ja) * 2013-07-30 2017-11-22 ユーハ味覚糖株式会社 グミキャンディ
WO2015035094A1 (en) 2013-09-04 2015-03-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
EP3216443A1 (en) 2016-03-10 2017-09-13 Athenion AG Beverage preparation capsule for delivery of a solubilisate
EP3388054A1 (en) 2017-04-12 2018-10-17 Athenion AG Dispensing cap containing a solubilisate of a pharmaceutically active agent or dietary supplement
EP3424494A1 (en) * 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
CN108271814A (zh) * 2018-01-21 2018-07-13 王小凤 一种糖尿病患者可食用的苹果的培育剂及其制备方法
CN108210360B (zh) * 2018-02-06 2021-02-12 德之馨(上海)有限公司 一种水溶性美白配方及其制备方法和用途
MA53966A (fr) 2018-10-24 2022-02-09 Syngenta Participations Ag Nouvelle composition de concentré soluble (sl) d'abamectine
WO2020250242A1 (en) * 2019-06-10 2020-12-17 Godrej Agrovet Limited Bud break formulation
JP7504589B2 (ja) * 2019-12-27 2024-06-24 ポーラ化成工業株式会社 透明な可溶化組成物
EP3909564A1 (de) 2020-05-12 2021-11-17 Metabolic Tuning AG Feste lösung aus gummi arabicum und wenigstens einem fettlöslichen wirkstoff
KR102365402B1 (ko) * 2021-05-31 2022-02-18 김상태 사포닌을 함유한 깻잎 및 이의 생산방법
CN115096678A (zh) * 2022-06-21 2022-09-23 杭州师范大学 一种基于聚乙二醇辅助机械无定形分散的植物中蒽醌类化合物的提取方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953496A (en) * 1958-12-02 1960-09-20 Upjohn Co Vitamin emulsion
CA1088427A (en) * 1975-12-22 1980-10-28 Andrew W. Finkstein Imidazoline-containing hair shampoo compositions
JPS5660565A (en) * 1979-10-22 1981-05-25 Dainichiseika Color Chem Composition for deodorizing aromatic
US4383987A (en) * 1981-06-26 1983-05-17 Colgate/Palmolive Company Foaming dentifrice containing nonionic surface active agent
GB2181737A (en) * 1985-08-29 1987-04-29 Avent Medical Ltd Liquid shampoo composition
US4810503A (en) * 1987-03-31 1989-03-07 Basf Corporation Polymers which form gels at low concentrations in water
ZA95519B (en) * 1994-02-07 1995-09-28 Isk Biotech Corp Pesticidal micronutrient com psitions containing zinc oxide
US5861174A (en) * 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6193954B1 (en) * 1997-03-21 2001-02-27 Abbott Laboratories Formulations for pulmonary delivery of dopamine agonists
US6027716A (en) * 1997-04-02 2000-02-22 Farmo-Nat Ltd. Synergistic herbal extracts
US6228347B1 (en) * 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
US6197305B1 (en) * 1998-01-05 2001-03-06 Farmo-Nat Ltd. Anti-fungal compositions with prolonged activity
US6200550B1 (en) * 1998-12-11 2001-03-13 Q-Pharma, Inc. Oral care compositions comprising coenzyme Q10
AUPP915099A0 (en) * 1999-03-12 1999-04-15 Monk, Michael Mendel Improved composition for oral administration
WO2000071163A1 (en) * 1999-05-24 2000-11-30 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
CA2383570C (en) * 1999-09-11 2008-08-12 The Procter & Gamble Company Pourable liquid vehicles
NL1014778C1 (nl) * 2000-03-29 2001-10-02 Giorgio Panin Een detergent samenstelling voor persoonlijke hygiÙne met een hoge inhoud aan vitamine E of derivaten daarvan.
DE10343872A1 (de) * 2003-09-23 2005-04-21 Bayer Cropscience Ag Suspensionskonzentrate
US7713440B2 (en) * 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
WO2005053652A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
US20060078616A1 (en) * 2004-08-30 2006-04-13 Georgewill Dawaye A Thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol

Also Published As

Publication number Publication date
EA026670B1 (ru) 2017-05-31
EP1993515B1 (de) 2009-07-29
KR20080108262A (ko) 2008-12-12
CA2643389C (en) 2014-12-02
US20140193513A1 (en) 2014-07-10
ES2330898T3 (es) 2009-12-16
HRP20090573T1 (hr) 2009-11-30
ATE437627T1 (de) 2009-08-15
CA2643389A1 (en) 2007-09-20
JP2009531305A (ja) 2009-09-03
KR101433962B1 (ko) 2014-08-25
AU2007224940B2 (en) 2013-08-29
US8703195B2 (en) 2014-04-22
PL1993515T3 (pl) 2010-01-29
DE502007001190D1 (de) 2009-09-10
JP2015028028A (ja) 2015-02-12
US20090280987A1 (en) 2009-11-12
WO2007104173A2 (de) 2007-09-20
BRPI0708773B1 (pt) 2021-10-19
US9114167B2 (en) 2015-08-25
EA200801850A1 (ru) 2009-06-30
EP1993515A2 (de) 2008-11-26
JP5678359B2 (ja) 2015-03-04
WO2007104173A3 (de) 2007-11-22
CN101400337A (zh) 2009-04-01
BRPI0708773A2 (pt) 2011-06-14
PT1993515E (pt) 2009-11-05
WO2007104173B1 (de) 2008-01-10
AU2007224940A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
DK1993515T3 (da) Fremgangsmåde til solubilisering, dispergering og stabilisering af stoffer, produkter, der er fremstillet efter fremgangsmåden og anvendelsen af samme
Sridharan et al. Jammed emulsions with adhesive pea protein particles for elastoplastic edible 3D printed materials
Vaia et al. Solvent-mediated disruption of bovine casein micelles at alkaline pH
ATE307611T1 (de) Flüssiges hochvisköses system mit gesteuerter freisetzung und medizinische oder chirurgische vorrichtung
BR112012027528A2 (pt) composição agroquímica estabilizada
EA201890637A1 (ru) Смешивание в процессе закачивания кислот и отклоняющих жидкостей с водорастворимыми замедляющими действие средствами
CO6331351A2 (es) Formulaciones que contienen celulosa bacteriana que carecen de un componente de carboximetilcelulosa.
EP4234632A3 (en) Core and shell polymers for 3d-printing
FR3060361B1 (fr) Emulsion eau-dans-huile comprenant un systeme emulsionnant particulier, une argile lipophile, une poudre d’organopolysiloxane elastomerique enrobee d’une resine de silicone
WO2009095562A3 (fr) Biomateriau permettant la delivrance controlee d'actifs
FR3030227B1 (fr) Emulsion stabilisees par des particules composites amphiphiles
NO20085175L (no) Konisk skrueblander.
BR112016028720A2 (pt) método para extração de contaminantes de produtos agricolas assim como dispositivo para tal finalidade
DE69906974D1 (de) Thixotrope formulierungen zur befüllung von gelatinekapseln
BR112017022686A2 (pt) método e aparelho para preparar uma solução médica.
MX382254B (es) Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina.
EA201900446A1 (ru) Композитный материал
Tarameshlou et al. A microfluidic approach to synthesize monodisperse poly (2-hydroxyethyl methacrylate) based spherical microgels via water in water emulsion technique
BR112018005531A2 (pt) materiais poliméricos
RU2009101084A (ru) Способ получения высокодисперсных биологически активных материалов
Kadla et al. Effect of hydrophilic and hydrophobic interactions on the rheological behavior and microstructure of a ternary cellulose acetate system
Arora et al. Rheology and stability of acidified food emulsions treated with high pressure
Mishra et al. Basil Oil-Based Nanoemulgel for Enhanced Delivery of Acetyl Keto Boswellic Acid: Formulation, Characterization, and Bioactivity Assessment
Wang et al. Ultrasonically Engineered Probiotic Particles as the Sole Stabilizer for Fucoxanthin-Loaded High Internal Phase Pickering Emulsions: Stability and Functional Study
Antsje et al. Encapsulation of GFP in Complex Coacervate Core Micelles